Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HLA-E inhibitors(major histocompatibility complex, class I, E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Abexxa Biologics, Inc.Startup |
Active Organization Abexxa Biologics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | Abexxa Biologics, Inc.Startup | 10 Jul 2020 |